| Literature DB >> 35480239 |
Yasaman Sanaei1, Mohsen Zeeb1, Seyed Saied Homami1, Amirhossein Monzavi2, Zahra Khodadadi1.
Abstract
A sustainable hybrid material based on carbonized cotton cloth/zeolite imidazolate framework-71/Fe3O4/polythionine (CC/ZIF-71/Fe3O4/PTh) was synthesized and applied in ultrasound-assisted dispersive magnetic solid-phase extraction (USA-DMSPE) followed with high performance liquid chromatography-ultraviolet detection (HPLC-UV) for simultaneous quantitation of diclofenac (DIC) and febuxostat (FEB) in human plasma. The surface of CC was modified with nanoarrays of zeolite imidazolate framework-71/Fe3O4/Polythionine. At first, an in situ synthesis of ZIF-71 in the presence of CC was carried out, and followed with magnetization process and oxidative polymerization of thionine. The nano-modifier agents improved the merits of the sorbent involving stability, porosity, mast transfer, π-π interactions and selectivity of CC. Characterizations of the hybrid sorbent were examined with different instrumental techniques. The limits of detection (LODs, S/N = 3) were recognized 2.1 ng mL-1 for DIC and 3.7 ng mL-1 for FEB. Acceptable linearity (0.992 ≤ r 2 ≤0.996) and relatively broad dynamic ranges of 10.0-1800.0 ng mL-1 and 15.0-2500.0 ng mL-1 were achieved for DIC and FEB, respectively. Reasonable intra-assay (≤7.2%, n = 9) and inter-assay (≤7.5%, n = 9) precisions as well as appropriate accuracies (≤8.0%) were provided illustrating applicability of the current approach for analytical purposes. Eventually, CC/ZIF-71/Fe3O4/PTh was employed as four-part sorbent for the assessment of DIC and FEB in human plasma at trace levels and subsequently main pharmacokinetic data such as T 1/2, T max, C max, and AUC0-24 of these drugs were comprehensively investigated. This journal is © The Royal Society of Chemistry.Entities:
Year: 2021 PMID: 35480239 PMCID: PMC9041133 DOI: 10.1039/d1ra04670e
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Scheme of CC/ZIF-71/Fe3O4/PTh preparation stages.
Fig. 2Schematic illustration of all routes of USA-DMSPE-HPLC-UV process for isolation and determination of DIC and FEB.
Fig. 3Field-emission scanning electron microscopy (FE-SEM) micrographs of (a) CC (b) CC/ZIF-71 (c) CC/ZIF-71/Fe3O4 (d) CC/ZIF-71/Fe3O4/PTh. Inset: magnified view of the nanoarray substances and CC.
Fig. 4(a) FTIR and (b) XRD spectra of sorbent through all the steps of synthesis.
Fig. 5Factors that influence the extraction efficiency. Effect of the amount of nanohybrid sorbent (a), pH (b), extraction time (c), the volume of ACN (d), ionic strength of sample media (e) on the extraction efficiency of DIC and FEB at concentration level of 150.0 ng mL−1 for each drug with a sample volume of 5.0 mL.
Analytical figures of merits of the USA-DMSPE-HPLC-UV for quantitation of target drugs
| Analyte | LDR | Linear equation | ( | LOD | LOQ | EF | ER |
|---|---|---|---|---|---|---|---|
| Diclofenac | 10.0–1800.0 |
| 0.992 | 2.1 | 10.0 | 37.5 | 93.9 |
| Febuxostat | 15.0–2500.0 |
| 0.996 | 3.7 | 15.0 | 34.4 | 86.1 |
Linear dynamic range (LDR).
Determination coefficient (r2).
Limit of detection (LOD).
Limit of quantification (LOQ).
Enrichment factor (EF).
Extraction recovery (ER).
Fig. 6HPLC chromatograms of blank sample (A) and spiked plasma (B–D). Chromatograms of B–D refer to 50.0, 100.0 and 175.0 ng mL−1 of both DIC and FEB, respectively.
Intra-day and inter-day accuracy and precision data in quantification of febuxostat and diclofenac in real media
| Drug | Concentration (ng mL−1) | Intra-day, | Inter-day, | ||||
|---|---|---|---|---|---|---|---|
| Found value ± SD | RSD | Accuracy | Found value ± SD (ng mL-1) | RSD (%) | Accuracy (%) | ||
| Diclofenac | 10.0 | 9.3 ± 0.5 | 5.4 | −7.0 | 9.2 ± 0.6 | 6.5 | −8.0 |
| 150.0 | 140.7 ± 9.3 | 6.6 | −6.2 | 159.1 ± 11.0 | 6.9 | +6.0 | |
| 1000.0 | 1053.0 ± 51.4 | 4.9 | +5.3 | 1066.3 ± 80.0 | 7.5 | +6.6 | |
| Febuxostat | 15.0 | 14.1 ± 0.9 | 6.4 | −6.0 | 13.8 ± 0.8 | 5.8 | −8.0 |
| 150.0 | 157.6 ± 10.5 | 6.7 | +5.1 | 139.2 ± 8.5 | 6.1 | −7.2 | |
| 1000.0 | 1062.1 ± 77.5 | 7.2 | +6.2 | 940.5 ± 63.4 | 6.7 | −5.9 | |
Standard deviation.
The average value of three independent measurements.
RSD is calculated based on the following equation SD/mean value × 100.
Accuracy is determined as (mean concentration found − known concentration)/(known concentration) × 100.
Pharmacokinetic parameters of diclofenac and febuxostat after oral administration of a fixed content combination tablet (100 mg diclofenac/40 mg febuxostat) to eight healthy volunteersa
| Pharmacokinetic feature | Mean ± SD | |
|---|---|---|
| Diclofenac | Febuxostat | |
|
| 2.88 ± 0.30 | 3.15 ± 0.27 |
|
| 1.62 ± 0.45 | 2.13 ± 0.60 |
| AUC0–24 (μg h mL−1) | 4.47 ± 0.35 | 5.66 ± 0.31 |
| AUC0–∞ (μg h mL−1) | 5.07 ± 0.52 | 6.18 ± 0.40 |
|
| 5.1 ± 1.1 | 6.3 ± 1.5 |
T max: time required for reaching maximum plasma concentration. Cmax: maximum plasma concentration. AUC 0–24: area under curve. AUC 0–∞: area under curve at infinite time. T½ (h): time required for reaching to half concentration.
The comparison of USA-DMSPE-HPLC-UV with previously reported methods for quantitation of diclofenac and febuxostat on real samplesa
| Instrument | Extraction method | Extraction phase | Drug | LOD (ng mL−1) | LOQ (ng mL−1) |
| RSD (%) | Matrix | Ref. |
|---|---|---|---|---|---|---|---|---|---|
| RP-HPLC | SALLE | Acetonitrile/ammonium acetate | FEB | 65.9 | 199.5 | 0.9997 | NR | Human plasma |
|
| RP-HPLC | LLE | Dichloromethane/isopropyl alcohol | DIC-P | 9.0 | 25.0 | 0.9994 | 2.4 and 1.9 | Human plasma |
|
| LC-ESI-MS/MS | LLE | Methyl | FEB | 2.5 | 50.0 | 0.9989 | NR | Human plasma |
|
| HPLC-DAD-FD | IL-DLLME | [BMIM][PF6]/[BMIM] [BF4] | DIC | 95.0 | 316.0 | 0.9995 | 3 | Water |
|
| FRET | Fluorimetric | — | FEB | 210.0 | 638.0 | 0.9995 | 0.68 to 1.76 | Human plasma |
|
| HPLC-UV | SBSE | PDMS | DIC | 12.03 | 36.37 | 0.9999 | NR | Urine |
|
| HPLC-UV | SPE | CTAB-coated Fe3O4 | DIC | 15.0 | NR | 0.9998 | 2.76 and 1.73 | Human plasma/Urine |
|
| RP-HPLC-UV | LLE | Diethyl ether | FEB | NR | 250.0 | NR | <15.0 | Human plasma |
|
| HPLC-UV | USA-DMSPE | CC/ZIF-71/Fe3O4/PTh | DIC-FEB | 2.1–3.7 | 10.0–15.0 | 0.992–0.996 | 7.2–7.5 | Human plasma | This work |
RP-HPLC: reverse phase high performance liquid chromatography method. HPLC-DAD-FD: high performance liquid chromatography-diode array-fluorescence detection. LC-ESI-MS/MS: liquid chromatography-tandem mass spectrometry. FRET: Förster or fluorescence resonance energy transfer. HPLC-UV: high-performance liquid chromatography with UV detection. RP-HPLC-UV: reverse phase high performance liquid chromatography method with UV detection. SALLE: salting-out assisted liquid–liquid extraction. LLE: liquid–liquid extraction. IL-DLLME: ionic liquids-dispersive liquid–liquid microextraction. SBSE: stir bar sorptive extraction. SPE: solid phase extraction. ([BMIM][PF6]): 1-butyl-3-methylimidazolium hexafluorophosphate. ([BMIM][BF4]): 1-butyl-3-methylimidazolium tetrafluoroborate. PDMS: polydimethylsiloxane. CTAB-coated Fe3O4: cetyltrimethyl ammonium bromide-coated Fe3O4. DIC-P: diclofenac potassium. NR: not reported.
Lower limit of quantification (LLOQ).